Wedbush analyst Liana Moussatos reiterated a Buy rating on Aimmune Therapeutics (AIMT – Research Report) today and set a price target of $79. The company’s shares opened today at $19.69, close to its 52-week low of $19.25.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -8.1% and a 33.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aimmune Therapeutics with a $54.29 average price target, which is a 175.7% upside from current levels. In a report issued on May 20, Credit Suisse also initiated coverage with a Buy rating on the stock with a $30 price target.
Based on Aimmune Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $54.27 million. In comparison, last year the company had a GAAP net loss of $49.5 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.